|
|
|
PDCs: The Next Frontier in Cancer Therapy
|
|
 |
|
| Antibody Drug Conjugates (ADCs) have made their mark, but it’s time to explore a new path. Peptide Drug Conjugates( PDCs) are emerging as a game-changing alternative, tackling the limitations of ADCs head-on and opening doors to more effective cancer treatments. In Biosynth’s latest white paper, we delve into the transformative potential of PDCs.
Discover how they achieve superior tumor penetration, boast higher drug-to-carrier ratios, and exhibit reduced immunogenicity. Explore the diverse targeting strategies and innovative linker technologies driving PDC development. Gain insights from preclinical and clinical data showcasing their efficacy and safety.
And stay ahead of the curve with emerging trends like constrained peptides and “on living cells” display technologies, poised to revolutionize cancer treatment.
Don’t miss this essential read for anyone passionate about advancing cancer research and drug development. |
|
|
|
|
|
|
|
| Therapeutics with a Sting: Venoms and Toxins |
|
 |
|
| Did you know that bee venom has many therapeutic properties and is composed of antimicrobial, anti-inflammatory, antioxidant, and radioprotective compounds? Bees are not the only organism to supply therapeutics with a sting. Even more remarkable, snake venom holds many potential pharmacological components, with some snake venom-derived drugs already approved by the FDA.
Venoms are not just made up of a single toxin but are instead made up of a natural pool of bioactive molecules, including enzymes, proteins, peptides, carbohydrates, metal ions, and lipids. That is why Biosynth has a venoms and toxins category, offering various animal-derived venoms and toxins with potential for biotechnological and pharmacological applications, including those derived from snakes, scorpions, spiders, cone snails, and reptiles.
|
|
|
|
|
|
|
|
| The Rise of Antimicrobial Peptides |
|
 |
|
Despite being one of the most significant breakthroughs in the history of medicine, antibiotics have been abused by humans in their use in medicine, animal husbandry, and agricultural applications, contributing to the impending global threat of antibiotic resistance. Can antimicrobial peptides offer an alternative to antibiotics?There is a promising solution to this crisis in the form of antimicrobial peptides (AMPs), the naturally occurring peptides protecting hosts from viruses, bacteria, fungi, and parasites. The fact that AMPs have broad-spectrum activity, immunomodulatory effects, do not affect microbiota, and are effective against microorganisms with antibiotic resistance means antimicrobial peptides are a valuable alternative to antibiotics. |
|
|
|
|
|
| Biosynth has a wide range of antimicrobial peptides in our catalog from cathelicidins and defensins to FDA-approved AMPs such as gramicidin, daptomycin, and colistin. Our state-of-the-art custom peptide services also allow us to synthesize optimized custom antimicrobial peptides for any AMP application, including GMP.
|
|
|
|
|
|
|
|
All of your Peptide Needs From One Provider
|
|
 |
|
| Get all of your peptide services from one global provider, with sites close to you wherever you are.
Here at Biosynth, we provide a full peptide service, from catalog peptides, peptide discovery and optimization, to large-scale manufacture and GMP manufacture. No project is too simple or too complex.
With specialist expertise in long, bridged, and labelled peptides as well as large-scale projects to supply hundreds of peptides or more, we have the scale and expertise to meet your needs.
|
|
|
|
|
|
|
|
|
|
Look out for Biosynth exhibits at these upcoming shows:
Boulder Peptide Symposium in Boulder, CO, USA, at booth 7 (Mon 16th Sep 2024 – Thu 19th Sep 2024)22nd Discovery on Target in Boston, MA, USA, attending (Mon 30th Sep 2024 – Thu 3rd Oct 2024)CPhI Worldwide in Milan, Italy, at booth 2D50 (Tue 8th Oct 2024 – Thu 10th Oct 2024)
|
|
|
|
|
|
|
|
|
|
|
